Format

Send to

Choose Destination
Anticancer Res. 2017 Oct;37(10):5553-5558.

Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.

Author information

1
St. Vinzenz Krankenhaus Betriebs GmbH, Zams, Austria e.woell@krankenhaus-zams.at.
2
Department of Internal Medicine IV, Klinikum Wels-Grieskirchen GmbH, Wels, Austria.
3
3rd Medical Department, Hanusch Hospital, Vienna, Austria.
4
St. John of God's Hospital, Vienna, Austria.
5
Medical University of Vienna, Vienna, Austria.
6
Medical University Hospital Innsbruck, Innsbruck, Austria.
7
Kepler Universitätsklinikum GmbH, Med Campus III, Klinik für Interne, Linz, Austria.
8
Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Innsbruck, Austria.
9
IIIrd Medical Department at the Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria.

Abstract

BACKGROUND/AIM:

Although high response rates using the doublet-chemotherapy of oxaliplatin and irinotecan as well as its combination with cetuximab in advanced gastric cancer were shown in previous trials, time to progression was short, suggesting acquired chemotherapy resistance.

PATIENTS AND METHODS:

Sequential chemotherapy (oxaliplatin and irinotecan followed by docetaxel) combined with bevacizumab was investigated in the GASTRIC-3 trial. Patients achieving at least stable disease were continued on maintenance bevacizumab.

RESULTS:

Objective response rate was available in 33 patients: Complete response (CR) 12.1%, partial response (PR) 39.4%, stable disease (SD) 27.3%. Median time to progression was 7.0 months (95%CI=5.0-11.0) and median overall survival was 11 months (95%CI=9.0-15.0). Of note, two patients continue to receive bevacizumab maintenance therapy for more than 5 years with ongoing CR.

CONCLUSION:

Combining sequential chemotherapy with oxaliplatin/irinotecan and docetaxel with bevacizumab followed by bevacizumab maintenance is feasible and clinically active in advanced gastric cancer.

KEYWORDS:

Gastric cancer; bevacizumab; maintenance

PMID:
28982869
DOI:
10.21873/anticanres.11987
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center